# **SMURF2** [GST-tagged]

E3 Ligase

Alternate Names: SMAD specific E3 ubiquitin protein ligase 2, MGC138150

**Cat. No. 63-0046-025** Quantity: 25 μg **Lot. No. 30231** Storage: -70°C

FOR RESEARCH USE ONLY NOT FOR USE IN HUMANS



**CERTIFICATE OF ANALYSIS Page 1 of 2** 

## **Background**

The enzymes of the ubiquitylation pathway play a pivotal role in a number of cellular processes including the regulated and targeted proteasomedependent degradation of substrate proteins. Three classes of enzymes are involved in the process of ubiquitylation; activating enzymes (E1s), conjugating enzymes (E2s) and protein ligases (E3s). Smad-Specific E3 Ubiquitin Protein Ligase 1 (SMURF2) is a member of the E3 protein ligase family and cloning of the human gene was first described by Kavsak et al. (2000). SMURF2 is a HECT domain ubiquitin E3 ligase that has been shown to regulate cell polarity, senescence and tumor suppression (Blank et al., 2012). Immunoprecipitation studies have demonstrated that SMURF2 interacts with RNF11 through the binding of the WW domain 2 and 3 of SMURF2 to the PY motif of RNF11. RNF11 was also found to interact with Ube2D1 in this complex and ubiquitylation of both SMURF2 and RNF11 was detected. (Subramaniam et al., 2003). Knock down of SMURF2 in human tumour cell lines results in increased levels of RNF20 and ubiquitylation of the RNF20 substrate histone H2B (Blank et al., 2012). SMURF2 knockout mice appear normal until early adulthood, when a large number of them develop tumours of all types (Blank et al., 2012).

#### References:

Blank M, Tang Y, Yamashita M, Burkett SS, Cheng SY et al. (2012) A tumor suppressor function of Smurf2 associated with controlling chromatin landscape and genome stability through RNF20. Nature Med 18, 227-234.

Continued on page 2

# **Physical Characteristics**

Species: human Protein Sequence: Please see page 2

Source: E. coli

Quantity: 25 µg

Concentration: 0.5 mg/ml

Formulation: 50 mM HEPES pH 7.5,

150 mM sodium chloride, 2 mM dithiothreitol, 10% glycerol

Molecular Weight: ~114 kDa

Purity: >90% by InstantBlue™ SDS-PAGE


Stability/Storage: 12 months at -70°C;

aliquot as required

# **Quality Assurance**


#### **Purity:**

4-12% gradient SDS-PAGE InstantBlue™ staining Lane 1: MW markers Lane 2: 1 µg GST-SMURF2



#### **Protein Identification:**

Confirmed by mass spectrometry.



E3 ligase assay: The ubiquitin conjugating activity of GST-SMURF2 was validated through its ability to catalyse the generation of polyubiquitin chains in the presence of the E1 activating enzyme His-UBE1, the E2 conjugating enzyme His-UBE2D3 (UbcH5c) (several E2s were tested, data generated with this E2 is provided by way of example) and ubiquitin. Incubation of GST-SMURF2 for 60 minutes at 30°C in the presence of ubiquitin, His-UBE1, His-UBE2D3 and ATP (Lane 1) was compared alongside two control reactions with either ATP (Lane 2) or GST-SMURF2 (Lane 3) excluded from the reaction. Ubiquitin conjugates were identified by Western blotting using an anti-ubiquitin conjugate antibody and these were observed only in the presence of both ATP and GST-SMURF2.



Dundee, Scotland, UK

#### **ORDERS / SALES SUPPORT**

#### **UK HQ and TECHNICAL SUPPORT**

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© **Ubiquigent 2014**. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0

# **SMURF2** [GST-tagged]

E3 Ligase

Alternate Names: SMAD specific E3 ubiquitin protein ligase 2, MGC138150

**Cat. No. 63-0046-025** Quantity: 25 μg **Lot. No. 30231** Storage: -70°C

FOR RESEARCH USE ONLY NOT FOR USE IN HUMANS



**CERTIFICATE OF ANALYSIS Page 2 of 2** 

### **Background**

#### Continued from page 1

Kavsak P, Rasmussen RK, Causing CG, Bonni S *et al.* (2000) Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF-beta receptor for degradation. *Molec Cell* **6**, 1365-1375.

Subramaniam V, Li H, Wong M, Kitching R, Attisano L, Wrana J, Zubovits J, Burger AM, Seth A (2003) The RING-H2 protein RNF11 is overexpressed in breast cancer and is a target of Smurf2 E3 ligase. *Brit J Cancer* 89, 1538-1544.

## **Physical Characteristics**

Continued from page 1

#### **Protein Sequence:**

MSPILGYWKIKGLVQPTRLLLEYLEEKY EEHLYERDEGDKWRNKKFELGLEFPN LPYYIDGDVKLTOSMAIIRYIADKHNMLG **GCPKERAEISMLEGAVLDIRYGVSRIAY** SKDFETLKVDFLSKLPEMLKMFEDRLCHK TYLNGDHVTHPDFMLYDALDVVLYMDPM CLDAFPKLVCFKKRIEAIPQIDKYLKSSKY IAWPLQGWQATFGGGDHPPKSDLEVLFQG PLGSPEIPGSTRAAAMSNPGRRRNGPVKLR LTVLCAKNLVKKDFFRLPDPFAKVVVDGS GQCHSTDTVKNTLDPKWNQHYDLYIGKSDS VTISVWNHKKIHKKQGAGFLGCVRLLSNAIN RLKDTGYQRLDLCKLGPNDNDTVRGQIVVS LQSRDRIGTGGQVVDCSRLFDNDLPDGWEER RTASGRIQYLNHITRTTQWERPTRPASEY SSPGRPLSCFVDENTPISGTNGATCGQSS DPRLAERRVRSQRHRNYMSRTHLHTPP DLPEGYEQRTTQQGQVYFLHTQTGVSTWH DPRVPRDLSNINCEELGPLPPGWEIRN TATGRVYFVDHNNRTTQFTDPRLSANL HLVLNRQNQLKDQQQQVVSLCPDDTE CLTVPRYKRDLVQKLKILRQELSQQQPQAGH CRIEVSREEIFEESYROVMKMRPKDLWKRL MIKFRGEEGLDYGGVAREWLYLLSHEMLN PYYGLFQYSRDDIYTLQINPDSAVNPEHLSY FHFVGRIMGMAVFHGHYIDGGFTLPFYKQLL GKSITLDDMELVDPDLHNSLVWILENDIT GVLDHTFCVEHNAYGEIIQHELKPNGK SIPVNEENKKEYVRLYVNWRFLRGIEAQFLA LOKGFNEVIPOHLLKTFDEKELELIICGLG KIDVNDWKVNTRLKHCTPDSNIVKWFWKAV EFFDEERRARLLQFVTGSSRVPLQGFKALQ GAAGPRLFTIHQIDACTNNLPKAHTCFNRID **IPPYESYEKLYEKLLTAIEETCGFAVE** 

Tag (**bold text**): N-terminal GST Protease cleavage site: PreScission™ (<u>LEVLFQ▼GP</u>) SMURF2 (regular text): Start **bold italics** (amino acid residues 1-748) Accession number: AAG45422.1



Dundee, Scotland, UK

#### **ORDERS / SALES SUPPORT**

International: +1-617-245-0020

US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233) Email: sales.support@ubiquigent.com

#### **UK HQ and TECHNICAL SUPPORT**

International: +44 (0) 1382 381147 (9AM-5PM UTC)
US/Canada: +1-617-245-0020 (9AM-5PM UTC)
Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© **Ubiquigent 2014**. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0